FR-BT-0003

Biological Age Biomarker Panels — Predictive Validity for Age-Related Decline

A blood-based biomarker panel can reliably predict biological age-related decline before clinical symptoms appear.

FragmentingVS-03·since 2026-09-25

Assessment trajectory

Fragmentingstate held · last assessed 2026-09-25

Verification Matrix

Verification position derived from the record’s assessments; dates show when Faultline first recorded each stage.

VS-01

Assertion

—

VS-02

Published evidence

—

VS-03

Audit

Current from 2026-09-25 — present

VS-04

Replication

First recorded 2024-01-15

VS-05

Operation

—

Stage first recorded Current verification position Not yet recorded

State Warrant

Current stateFragmentingVS-03

Why this state?Normal Record Review of the 2025 candidate held outside LPR-001-D27. The legacy correction and AS-001/AS-002 remain unchanged. IN-006 is a new evidence instance with structured source provenance; no claim-resolution or clinical-utility finding is inferred.

Assessment summaryNormal Record Review admits Oh et al. (2025) as IN-006. In 44,498 UK Biobank participants, plasma-protein estimates of 11 organ ages were associated with subsequent organ-related disease and mortality over 2–17 years of follow-up. The brain-age association with later Alzheimer's disease persisted after adjustment for APOE genotype, and mortality associations added information beyond PhenoAge and cystatin C. This materially strengthens the prospective, organ-specific blood-panel evidence and narrows the uncertainty recorded after LPR-001-D27: the question is no longer whether blood can show organ-specific prospective outcome associations. The study still does not establish externally calibrated absolute risk for a defined asymptomatic patient, dependable performance across settings and specimen platforms for specified outcomes, or improved outcomes from acting on the score. FRAGMENTING / VS-03 is reaffirmed on that narrower individual prediction and decision boundary; the prospective cohort result must not be dismissed as only cross-sectional age correlation.

State entered2024-01-15

Last reaffirmed2026-09-25

Mechanisms

Causal mechanisms recorded for this claim. The State Warrant above remains the authoritative current assessment.

BOTTLENECK — MEASUREMENT VALIDITYBN-001

Blood panel as proxy for future individual decline. Oh et al. (2023) show that organ-enriched plasma proteins yield organ-specific age estimates associated with disease and mortality; their 2025 UK Biobank analysis adds prospective organ-related disease and mortality associations, including information beyond selected established biomarkers for mortality. The unresolved measurement question is externally calibrated, transportable absolute risk for a defined asymptomatic individual's particular later decline, with useful discrimination and incremental value against appropriate clinical predictors for each outcome. Cohort hazard associations do not by themselves establish dependable patient-level predictions or a beneficial clinical decision. This remains a proxy-measurement bottleneck in the sense of RN-005.

Resistance MechanismRM-001

Validation requires longitudinal follow-up and transportability testing. The 2025 UK Biobank analysis provides substantial baseline-to-outcome follow-up, so a categorical absence of longitudinal evidence is no longer accurate. Disease-specific absolute-risk calibration, performance in independent clinical populations and across assays, and the consequences of clinical decisions still require long-horizon validation. This biological-time lag compounds BN-001: cohort associations can be established before a panel is reliable and useful for a particular patient's pre-symptomatic decision.

AttractorAT-001

Externally validated organ-specific absolute-risk prediction and individual trajectory modelling. Organ-enriched plasma-protein models now show prospective associations with incident disease and mortality in a large UK Biobank cohort. The next resolution step is an independently validated, pre-symptomatic panel that gives calibrated risks for specified decline pathways in individual patients, adds useful discrimination beyond relevant clinical predictors across settings and assays, and has an appropriate decision boundary. Multi-omic and repeated-measure designs may help, but another organ-age estimate or cohort hazard ratio alone does not complete this attractor.

Assessment History

2024-01-15

Initial assessment — Fragmenting

The claim is partially supported and fragmenting. Blood-based biomarker panels demonstrate population-level predictive validity for biological aging outcomes — at the population level, high biological age scores predict faster subsequent decline, higher mortality risk, and earlier disease onset. This is well-established across multiple panel types (epigenetic, proteomic, metabolomic) and multiple longitudinal cohorts. The population-level claim is supported. The claim fragments at the individual level. Different biological age clocks give substantially different estimates for the same individual, and organ systems within one person age at markedly different rates (INST-003): a blood panel captures a composite population-level signal that may not reflect which specific organ or process is declining fastest in any given person. The pressure state is FRAGMENTING: population-level predictive validity is well established, but individual-level predictive validity — the form the claim requires for clinical use — has not been demonstrated, and the actionability gap identified in DunedinPACE (INST-004) means that even a valid individual-level signal may not yet translate into a clear intervention (BN-001).

Verification Stage: VS-04 after ratified review (stored code VS-03 preserved).^*

2026-09-25

Reassessed, no change — Fragmenting

LPR-001-D27 corrects the legacy warrant without reversing the record. Horvath, PhenoAge and GrimAge remain the strongest retained longitudinal evidence for blood methylation measures and later health outcomes. Lehallier (2019) establishes age-associated plasma-protein patterns but not the prospective mortality, frailty and disease predictions formerly attributed to it. Ahadi's molecular ageotypes and Oh's organ-specific blood-protein models are distinct results: the latter demonstrates that organ-specific signals can be recovered from blood and related to disease and mortality risks. DunedinPACE (2022) supports group-level associations with morbidity, disability and mortality, with incremental prediction beyond GrimAge; whether a score guides an effective intervention remains a separate clinical-utility question. The named consumer products use blood, saliva and cheek-swab samples respectively, so their collective deployment does not establish this blood-panel claim. FRAGMENTING / VS-03 remains warranted on the narrower distinction between cohort-level predictive associations and validated prospective, individual-specific, pre-symptomatic decisions. This is an unresolved validation question, not proof that blood cannot contain organ-specific information.

Corrective assessment appended after LPR-001-D27. AS-001 remains historical. No 2025 or later scientific result admitted through this provenance correction.

2026-09-25

Reassessed, no change — Fragmenting

Normal Record Review admits Oh et al. (2025) as IN-006. In 44,498 UK Biobank participants, plasma-protein estimates of 11 organ ages were associated with subsequent organ-related disease and mortality over 2–17 years of follow-up. The brain-age association with later Alzheimer's disease persisted after adjustment for APOE genotype, and mortality associations added information beyond PhenoAge and cystatin C. This materially strengthens the prospective, organ-specific blood-panel evidence and narrows the uncertainty recorded after LPR-001-D27: the question is no longer whether blood can show organ-specific prospective outcome associations. The study still does not establish externally calibrated absolute risk for a defined asymptomatic patient, dependable performance across settings and specimen platforms for specified outcomes, or improved outcomes from acting on the score. FRAGMENTING / VS-03 is reaffirmed on that narrower individual prediction and decision boundary; the prospective cohort result must not be dismissed as only cross-sectional age correlation.

Normal Record Review of the 2025 candidate held outside LPR-001-D27. The legacy correction and AS-001/AS-002 remain unchanged. IN-006 is a new evidence instance with structured source provenance; no claim-resolution or clinical-utility finding is inferred.

Claim Lineage

Historical narrative recorded for this claim. It does not override the current State Warrant.

2013

First epigenetic clocks demonstrate predictive validity. Horvath and Hannum clocks show methylation patterns predict chronological age; early mortality prediction signals emerge. Population-level predictive validity is established as a realistic goal.

2018–19

PhenoAge and GrimAge link methylation measures to health outcomes. Lehallier et al. identify nonlinear age-associated plasma-protein patterns; that study does not establish prospective mortality, frailty or disease-incidence prediction by its panel.

2020–23

Ahadi et al. describe individual molecular ageotypes; Oh et al. use plasma proteins to estimate age across 11 organs and associate organ-age signals with disease and mortality risk. Blood can contain organ-specific information, while individual prospective calibration remains open.

2022–24

DunedinPACE (2022) reports morbidity, disability and mortality associations and incremental prediction beyond GrimAge. Consumer biological-age tests use differing specimen types; commercial availability does not validate the blood-panel claim or establish clinical utility.

2025

Oh et al. report 11 organ-specific plasma-protein age estimates in 44,498 UK Biobank participants and associations with later organ-related disease and mortality over 2–17 years. This advances prospective organ-specific evidence; external patient-level calibration and clinical utility remain open.

Open Questions

Questions retained in this record. The current State Warrant may have narrowed or reframed earlier questions.

OQ-001

Given Oh et al.'s organ-specific plasma-protein signals, can a defined baseline blood panel predict a particular asymptomatic individual's future decline pathway with reliable calibration and incremental value over clinical risk factors?

Raised 2024-01-15

OQ-002

Which commercial assay deployments, if any, are sufficiently specific to the blood-panel claim to count as anticipatory institutional evidence? The former seventh-occurrence count included saliva and cheek-swab products and is withdrawn; company-funded validation still warrants independent scrutiny.

Raised 2024-01-15

OQ-003

FR-BT-0003 is the third record in PROG-BT, and measurement validity pressure has now appeared in all three. Is this the diagnostic signal that transforms the PROG-BT tendency into a full programme diagnosis? Or does the Observatory require more records before naming the diagnosis?

Raised 2024-01-15

Mutation Log

Mutation	Date	Field	Prior value	Current value
M-008	2026-09-25	record_review	LPR-001-D27 held 2025 organ-proteomics candidate	IN-006 admitted; AS-003 reaffirmed FRAGMENTING / VS-03
M-007	2026-09-25	provenance_correction	LPR-001-D27 discrepancies_found / pending	LPR-001-D27 discrepancies_corrected / completed
M-006	2026-09-06	description_restored	Legacy ingestion cutoffs: mechanisms:BN-001, mechanisms:RM-001, mechanisms:AT-001	Source-restored complete descriptions
M-005	2024-01-15	rn_005_condition_confirmed	—	RN-005-CONDITION-CONFIRMED
M-004	2024-01-15	mechanisms_recorded	—	MECHANISMS-RECORDED
M-003	2024-01-15	assessment_issued	—	ASSESSMENT-ISSUED
M-002	2024-01-15	instances_logged	—	INSTANCES-LOGGED
M-001	2024-01-15	record_created	—	RECORD-CREATED

Evidence Sources

6 instances on recordShow sources ↓Hide ↑

IN-001Epigenetic clock development — Horvath, Hannum, GrimAgesupportive

IN-002Proteomics-based aging clocks — SomaScan and multi-omic panels1. Lehallier et al., Undulating changes in human plasma proteome profiles across the lifespan, Nature Medicine 25, 1843–1850 (2019) DOI 10.1038/s41591-019-0673-2 · Abstract — 2,925 proteins, 4,263 people, nonlinear age-related proteome changes and disease-trait associationssupportive

IN-003Individual ageotypes and organ-specific plasma-protein aging signatures1. Ahadi et al., Personal aging markers and ageotypes revealed by deep longitudinal profiling, Nature Medicine 26, 83–90 (2020) DOI 10.1038/s41591-019-0719-5 · Abstract — longitudinal multiomics of 106 people and individualized molecular ageotypes2. Oh et al., Organ aging signatures in the plasma proteome track health and disease, Nature 624, 164–172 (2023) DOI 10.1038/s41586-023-06802-1 · Abstract — organ-enriched plasma-protein models across 11 organs, cohort replication and associations with organ disease and mortalitypartial

IN-004DunedinPACE and pace-of-aging measures — actionability gap1. Belsky et al., DunedinPACE, a DNA methylation biomarker of the pace of aging, eLife 11:e73420 (2022) DOI 10.7554/eLife.73420 · Abstract and cohort analyses — morbidity, disability, mortality, comparison with GrimAge and incremental predictionsupportive

IN-005Commercial deployment — Elysium Health, InsideTracker, Tally Health1. InsideTracker, InnerAge 2.0 blood-biomarker test · Product method — blood biomarkers2. Elysium Health, Index epigenetic biological age test · Product FAQ — saliva-derived DNA methylation3. Tally Health, TallyAge test method · Product method — cheek-cell swab DNA methylationneutral

IN-006Organ-specific plasma-protein age estimates and subsequent disease and mortality — Oh et al. 20251. Oh et al., Plasma proteomics links brain and immune system aging with healthspan and longevity, Nature Medicine 31, 2703–2711 (2025) DOI 10.1038/s41591-025-03798-1 · Abstract, organ-age/incident-disease and mortality Results, Discussion — 44,498 UK Biobank participants, 2,916 proteins, 11 organs, prospective associations and validation limitssupportive